Molecular Basis of Esophageal Cancer Development and Progression

Surgical Clinics of North America

Volumn 92, Issue 5, 2012, Pages 1089-1103

  Denlinger, Chadrick E ^a   Thompson, Robert K ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Adenocarcinoma; Barrett esophagus; Esophageal cancer; Molecular biology; Squamous cell carcinoma; Targeted therapy

Indexed keywords

ACETALDEHYDE; ACETIC ACID; ALDEHYDE DEHYDROGENASE ISOENZYME 2; BEVACIZUMAB; BILE SALT; BONE MORPHOGENETIC PROTEIN 4; BRCA1 PROTEIN; CETUXIMAB; CISPLATIN; CYCLIN D; CYCLOOXYGENASE 2; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; PACLITAXEL; PANITUMUMAB; PROTEIN P16; PROTEIN P21; PROTEIN P53; PROTON PUMP INHIBITOR; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR CDX1; TRANSCRIPTION FACTOR CDX2; TRASTUZUMAB; UVOMORULIN; VASCULOTROPIN ANTIBODY;

ALCOHOL CONSUMPTION; AUTOPHOSPHORYLATION; BARRETT ESOPHAGUS; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CARCINOGENICITY; CELL PH; CELL PROLIFERATION; CELL TRANSDIFFERENTIATION; CHROMOSOME 17Q; CHRONIC INFLAMMATION; DISEASE FREE SURVIVAL; ENZYME ACTIVATION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; EXCISION REPAIR; GASTROESOPHAGEAL REFLUX; GENE MUTATION; HISTOLOGY; HUMAN; LONG TERM EXPOSURE; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; OBESITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SMOKING; SQUAMOUS EPITHELIUM; STOMACH CONTENT; STOMACH PH;

ADENOCARCINOMA; ALCOHOL DRINKING; BARRETT ESOPHAGUS; BIOLOGICAL MARKERS; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; SMOKING;

EID: 84866879803     PISSN: 00396109     EISSN: 15583171     Source Type: Journal    
DOI: 10.1016/j.suc.2012.07.002     Document Type: Review

References (51)

1. Oberg S., Peters J.H., DeMeester T.R., et al. Determinates of intestinal metaplasia within the columnar lined esophagus. Arch Surg 2000, 135:651-656.
2. Dvorak K., Goldman A., Kong J., et al. Molecular mechanisms of Barrett's esophagus and adenocarcinoma. Ann N Y Acad Sci 2011, 1232:381-391.
3. Groisman G.M., Amar M., Meir A. Expression of the intestinal marker Cdx2 in the columnar-lined esophagus with and without intestinal (Barrett's) metaplasia. Mod Pathol 2004, 17:1282-1288.
4. Steininger H., Pfofe D.A., Muller H., et al. Expression of CDX2 and MUC2 in Barrett's mucosa. Pathol Res Pract 2005, 2018:573-577.
5. Braunstein E.M., Qiao X.T., Madison B., et al. Villin: a marker for development of the epithelial pyloric border. Dev Dyn 2002, 224:90-102.
6. Park J., Schulz S., Waldman S.A. Intestine-specific activity of the human guanylyl cyclase C promoter is regulated by Cdx2. Gastroenterology 2000, 119:89-96.
7. Hu Y., Williams V.A., Gellerson O., et al. The pathogenesis of Barrett's esophagus: secondary bile acids upregulates intestinal differentiation factor CDX2 expression in esophageal cells. J Gastrointest Surg 2007, 142:540-545.
8. Avissar N.E., Toia L., Hu Y., et al. Bile acid alone, or in combination with acid, induces CDX2 expression through activation of the epidermal growth factor receptor (EGFR). J Gastrointest Surg 2009, 13:212-222.
9. Anisfeld A.M., Kast-Woelbern H.R., Lee H., et al. Activation of the nuclear factor receptor FXR induces fibrinogen expression: a new role for bile acid signaling. J Lipid Res 2005, 46:458-468.
10. Kaur B.S., Triadafelopoulos G. Acid and bile-induced PGE(2) release and hyperproliferation in Barrett's esophagus are COX-2 and PKC-epsilon dependent. Am J Physiol Gastrointest Liver Physiol 2002, 283:G327-G334.
11. Milano F., van Baal J.W., Buttat N.S., et al. Bone morphogenetic protein 4 expressed in esophagitis induces a columnar phenotype in esophageal squamous cells. Gastroenterology 2007, 132:2412-2421.
12. LeBoeuf R.A., Kerckaert G.A. The induction of transformed-like morphology and enhanced growth in Syrian hamster embryo cells grown at acid pH. Carcinogenesis 1986, 7:1431-1440.
13. Merchant N.P., Rogers C.M., Trivedi B., et al. Ligand-dependent activation of the epithelial growth factor receptor by secondary bile acids in polarizing colon cancer cells. Surgery 2005, 138:415-421.
14. Jaiswal K., Lopez-Guzman C., Souza R.F., et al. Bile salt exposure increases proliferation through p38 and ERK MAPK pathways in a non-neoplastic Barrett's cell line. Am J Physiol Gastrointest Liver Physiol 2006, 290:G335-G342.
15. + exchanger: implication for Barrett's oesophagus. Gut 2010, 59:1606-1616.
16. Hutchinson L., Stenstrom B., Chen D., et al. Human Barrett's adenocarcinoma of the esophagus, associated myofibroblasts, and endothelium can arise from bone marrow-derived cells after allogeneic stem cell transplant. Stem Cells Dev 2011, 20:11-17.
17. Korbling M., Katz R.L., Khanna A., et al. Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells. N Engl J Med 2002, 346:738-746.
18. Chen H., Fang Y., Tevebaugh W., et al. Molecular mechanisms of Barrett's esophagus. Dig Dis Sci 2011, 56:3405-3420.
19. Das K.M., Kong Y., Bajpai M., et al. Transformation of benign Barrett's epithelium by repeated acid and bile exposure over 65 weeks: a novel in vitro model. Int J Cancer 2011, 128:274-282.
20. Fang D., Kas K.M., Cao W., et al. Barrett's esophagus: progression to adenocarcinoma and markers. Ann N Y Acad Sci 2011, 1232:210-229.
21. Hong H., Resnick M., Behar J., et al. Acid-induced p16 hypermethylation contributes to development of esophageal adenocarcinoma via activation of NADPH oxidase NOS5-S. Am J Physiol Gastrointest Liver Physiol 2010, 299:G697-G706.
22. Fu X., Beer D.G., Behar J., et al. cAMP-response element-binding protein mediates acid-induced NADPH oxidase NOX5-S expression in Barrett's esophageal adenocarcinoma cells. J Biol Chem 2006, 281:20368-20382.
23. Si J., Fu X., Behar J., et al. NADPH oxidase NOX5-S mediates acid induced cyclooxygenase-2 expression via activation of NF-κB in Barrett's esophageal adenocarcinoma cells. J Biol Chem 2007, 282:16244-16255.
24. Jin Z., Cheng Y., Gu W., et al. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction of Barrett's esophagus. Cancer Res 2009, 69:4112-4115.
25. Kwak E.L., Jankowski J., Thayer S.P., et al. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 2006, 12:4283-4287.
26. Rygiel A.M., Milano F., Ten Kate F.J., et al. Gains and amplifications of c-myc, EGFR, and 20.Q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2008, 17:1380-1385.
27. Friess H., Fukuda A., Tang W.H., et al. Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbb-2 and c-erbb-3. World J Surg 1999, 23:1010-1018.
28. Wilkinson N.W., Black J.D., Roukhadze E., et al. Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg 2004, 8:448-453.
29. Pinto C., Di Fabio F., Siena S., et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. Ann Oncol 2007, 18:510-517.
30. Moehler M., Eimermacher A., Siebler J., et al. Randomized phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILP) vs. 5-fluorouracil, leucovorin and etoposide (ELF) in untreated gastric cancer. Br J Cancer 2005, 92:2122-2128.
31. Javle M., Pande A., Iyer R., et al. Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response. Am J Clin Oncol 2008, 31:329-334.
32. Ferry D.R., Anderson M., Beddard K., et al. A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res 2007, 13:5869-5875.
33. Dragovich T., McCoy S., Fenoglio-Preiser C.M., et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006, 24:4922-4927.
34. Burnat G., Rau T., Elshimi E., et al. Bile acids induce overexpression of homeobox gene CDX-2 and vascular endothelial growth factor (VEGF) in human Barrett's esophageal mucosa and adenocarcinoma cell line. Scand J Gastroenterol 2007, 42:1460-1465.
35. Shah M.A., Jhawer M., Ilson D.H., et al. Phase II study of modified docetaxel, cisplatin and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 2011, 29:868-874.
36. Yoon H.H., Shi Q., Sukov W.R., et al. Association of her2/erbb2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res 2012, 18:546-554.
37. Safran H., Dipetrillo T., Akerman P., et al. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 2007, 67:405-409.
38. Brien T.P., Odze R.D., Sheehan C.E., et al. Her-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. Hum Pathol 2000, 31:35-39.
39. Bang Y.J., van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive gastric or gastro-oesophageal junction cancer (toGA): a phase 3, open-label, randomized controlled trial. Lancet 2010, 28:687-697.
40. Belkhiri A., Zaika A., Pidkovka N., et al. DARPP-32: a novel antiapoptotic gene in upper gastrointestinal carcinomas. Cancer Res 2005, 65:6583-6592.
41. Seitz H.K., Stickel F. Molecular mechanisms of alcohol mediated carcinogenesis. Nat Rev Cancer 2007, 7:599-612.
42. Yokoyama A., Kumagai Y., Yokoyama T., et al. Health risk appraisal models for mass screening for esophageal and pharyngeal cancer: an endoscopic follow-up study of cancer-free Japanese men. Cancer Epidemiol Biomarkers Prev 2009, 18:651-655.
43. Homann N., Tillonen J., Meurman J.H., et al. Increased salivary acetaldehyde levels in heavy drinkers and smokers: a microbiological approach to oral cavity cancer. Carcinogenesis 2000, 21:663-668.
44. Shimizu M., Lasker J.M., Tsutsumi M., et al. Immunohistochemical localization of ethanol-induced P450IIE1 in the rat alimentary tract. Gastroenterology 1990, 99:1044-1053.
45. Choi S.W., Stickel F., Baik H.W., et al. Chronic alcohol consumption induces genomic but not p53-specific DNA hypomethylation in rat colon. J Nutr 1999, 129:1945-1950.
46. Toh Y., Oki E., Ohgaki K., et al. Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus; molecular mechanisms of carcinogenesis. Int J Clin Oncol 2010, 15:135-144.
47. Salaspuro V., Salaspuro M. Synergistic effect of alcohol drinking and smoking on in vivo acetaldehyde concentration in saliva. Int J Cancer 2004, 111:480-483.
48. Pfeifer G.P., Denissenko M.F., Olivier M., et al. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 2002, 21:7435-7451.
49. Janmaat M.L., Gallegos-Ruiz M.I., Rodriguez J.A., et al. Predictive factors for outcomes in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006, 24:1612-1619.
50. Ilson D.H., Kelsen D., Shah M., et al. A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer 2011, 117:1409-1414.
51. Cooper J.S., Gui M.D., Herskovic A., et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow up of a prospective randomized trial (RTOG 85-01). JAMA 1999, 281:1623-1627.